Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Paclitaxel resistance related to nuclear envelope structural sturdiness
Elizabeth R. Smith, Jing‐Quan Wang, Dong‐Hua Yang, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100881-100881
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin
Jun Yang, Nanjing Li, Xinyu Zhao, et al.
Biochemical Pharmacology (2024) Vol. 221, pp. 116040-116040
Closed Access | Times Cited: 9
Cell death in cancer chemotherapy using taxanes
Ana P. Xu, Lucy B. Xu, Elizabeth R. Smith, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 8
Alkaliptosis induction counteracts paclitaxel‐resistant ovarian cancer cells via ATP6V0D1‐mediated ABCB1 inhibition
Fangquan Chen, Junhao Lin, Rui Kang, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 8, pp. 1515-1527
Closed Access | Times Cited: 7
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges
Changyun Li, Wanhe Wang, Chung‐Hang Leung, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes
Ruoqi Li, Lei Yan, Jingwei Jiu, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 4, pp. 1452-1470
Open Access | Times Cited: 6
Golgi scaffold protein PAQR11 in pan-cancer landscape: a comprehensive bioinformatics exploration of expression patterns, prognostic significance, and potential immunological function
Zhu Liu, Zhi‐Qiang Ling
Heliyon (2025) Vol. 11, Iss. 2, pp. e41724-e41724
Closed Access
The Second Selectivity of Taxanes to Malignant Cells --- Nuclear Envelope Malleability
Xiang‐Xi Xu, Elizabeth R. Smith
Journal of Cancer (2025) Vol. 16, Iss. 4, pp. 1051-1053
Open Access
Plant-derived compounds with antineoplastic activity: a literature review
Márlon de Castro Vasconcelos, Mayron Guedes Silva, Raphael Guedes Silva, et al.
Caderno Pedagógico (2025) Vol. 22, Iss. 1, pp. e13488-e13488
Closed Access
Nanotheranostics with Radionuclides for Cancer Diagnosis and Therapy
Minhui Cui, Mengmeng Zhu, Dongsheng Tang, et al.
Advanced Functional Materials (2025)
Closed Access
STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis
Chuanli Gao, Hui Yang, Cheng Jiao, et al.
Medical Oncology (2025) Vol. 42, Iss. 3
Closed Access
Ultrasound-triggered lysosomal alkalinization to block autophagy in tumor therapy
Yanbiao Liu, Bowen Li, Run Yang, et al.
Biomaterials (2025), pp. 123250-123250
Closed Access
Natural aporphine alkaloids: A comprehensive review of phytochemistry, pharmacokinetics, anticancer activities, and clinical application
Jing Sun, Xingtian Zhan, Weimin Wang, et al.
Journal of Advanced Research (2023) Vol. 63, pp. 231-253
Open Access | Times Cited: 12
Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA
Simin Ye, Shiyu Chen, Xiaoyan Yang, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Exploiting Matrix Stiffness to Overcome Drug Resistance
Hakan Berk Aydın, Altuğ Özçelikkale, Ahmet Acar
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 8, pp. 4682-4700
Open Access | Times Cited: 4
ABCB1‐mediated docetaxel resistance reversed by erastin in prostate cancer
Fangfang Chen, Shiqi Wu, Ni Kuang, et al.
FEBS Journal (2024) Vol. 291, Iss. 14, pp. 3249-3266
Closed Access | Times Cited: 3
Ecological and evolutionary dynamics to design and improve ovarian cancer treatment
Grace Han, Monica Alexander, Julia Gattozzi, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 9
Open Access | Times Cited: 3
Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance
Meiying Qin, Chunmei Zhang, Li Yang
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Role of Exosomal MicroRNAs in Modulating the Response of Cancer Cells to Paclitaxel Treatment
Lanqing Zhao, Cheng Lv, Hui Xie, et al.
Journal of Cellular Signaling (2024) Vol. 5, Iss. 1, pp. 41-50
Open Access | Times Cited: 2
Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling
Jiying Liu, G. Fang, Cong Lan, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 767-780
Open Access | Times Cited: 2
Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options
Mariana Nunes, Carla Bartosch, Miguel Henriques Abreu, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 786-786
Open Access | Times Cited: 2
Two-Photon Absorption Aggregation-Induced Emission Luminogen/Paclitaxel Nanoparticles for Cancer Theranostics
Liwei Zhu, Yiming Wang, Jiayi Song, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 21, pp. 27075-27086
Closed Access | Times Cited: 2
Benserazide, a cystathionine beta-synthase (CBS) inhibitor, potentially enhances the anticancer effects of paclitaxel via inhibiting the S-sulfhydration of SIRT1 and the HIF1-α/VEGF pathway
Wei Zhao, Shasha Feng, Jian Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy
Chengyong Wu, Lele Zhang, Zhilan Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116649-116649
Closed Access | Times Cited: 2
LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy
Ali G. Alkhathami, Harikumar Pallathadka, Sejal Shah, et al.
Medical Oncology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 2
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer
Wenhan Li, Yuhui Huang, Xiao Man, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109160-109160
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top